Glypican-3 level assessed by the enzyme-linked immunosorbent assay is inferior to alpha-fetoprotein level for hepatocellular carcinoma diagnosis
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background/Aims: Glypican-3 (GPC3) protein is highly expressed in hepatocellular carcinoma (HCC) tissue. It has been suggested as a diagnostic biomarker, but its inconsistent performance means that it requires further assessment. We therefore investigated the diagnostic value of the plasma GPC3 level compared to the alpha-fetoprotein (AFP) level as a diagnostic biomarker of HCC. Methods: We enrolled 157 consecutive patients with newly diagnosed HCC and 156 patients with liver cirrhosis (LC) as the control group. GPC3 plasma levels were measured using two commercially available enzyme-linked immunosorbent assays (ELISAs, named as Assay 1 and 2), and AFP levels were measured using an enzyme-linked chemiluminescent immunoassay. The diagnostic accuracy was analyzed using the receiver operating characteristics (ROC) curve. Results: Plasma GPC3 levels in HCC patients were very low (0–3.09 ng/mL) in Assay 1, while only 3 of the 157 patients (1.9%) showed detectable GPC3 levels in Assay 2. The median GPC3 level was not significantly elevated in the HCC group (0.80 ng/mL) compared with the LC group (0.60 ng/mL). The area under the ROC curve (AUC) for GPC3 was 0.559 in Assay 1. In contrast, the median AFP level was significantly higher in HCC (27.72 ng/mL) than in LC (4.74 ng/mL), with an AUC of 0.729. Conclusions: The plasma level of GPC3 is a poor diagnostic marker for HCC, being far inferior to AFP. The development of a consistent detection system for the blood level of GPC3 is warranted. (Clin Mol Hepatol 2016;22:359-365)
Abstract
Background/Aims: Glypican-3 (GPC3) protein is highly expressed in hepatocellular carcinoma (HCC) tissue. It has been suggested as a diagnostic biomarker, but its inconsistent performance means that it requires further assessment. We therefore investigated the diagnostic value of the plasma GPC3 level compared to the alpha-fetoprotein (AFP) level as a diagnostic biomarker of HCC. Methods: We enrolled 157 consecutive patients with newly diagnosed HCC and 156 patients with liver cirrhosis (LC) as the control group. GPC3 plasma levels were measured using two commercially available enzyme-linked immunosorbent assays (ELISAs, named as Assay 1 and 2), and AFP levels were measured using an enzyme-linked chemiluminescent immunoassay. The diagnostic accuracy was analyzed using the receiver operating characteristics (ROC) curve. Results: Plasma GPC3 levels in HCC patients were very low (0–3.09 ng/mL) in Assay 1, while only 3 of the 157 patients (1.9%) showed detectable GPC3 levels in Assay 2. The median GPC3 level was not significantly elevated in the HCC group (0.80 ng/mL) compared with the LC group (0.60 ng/mL). The area under the ROC curve (AUC) for GPC3 was 0.559 in Assay 1. In contrast, the median AFP level was significantly higher in HCC (27.72 ng/mL) than in LC (4.74 ng/mL), with an AUC of 0.729. Conclusions: The plasma level of GPC3 is a poor diagnostic marker for HCC, being far inferior to AFP. The development of a consistent detection system for the blood level of GPC3 is warranted. (Clin Mol Hepatol 2016;22:359-365)
참고문헌 (24)
- Feng M, "Glypican-3 antibodies: a new therapeutic target for liver cancer", FEBS Lett, 588, pp.377~382 (2014)
- Zhu AX, "First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma", Clin Cancer Res, 19, pp.920~928 (2013)
- Omata M, "Asian Pacific Association for the Study of the Liver consensus recommendations on hepatocellular carcinoma", Hepatol Int, 4, pp.439~474 (2010)
- Song do S, "Changes of guidelines diagnosing hepatocellular carcinoma during the last ten-year period", Clin Mol Hepatol, 18, pp.258~267 (2012)
- Capurro M, "Glypican-3: a novel serum and histochemical marker for hepatocellular carcinoma", Gastroenterology, 125, pp.89~97 (2003)
- Liu XF, "Diagnostic accuracy of serum glypican-3 for hepatocellular carcinoma: a systematic review and meta-analysis", Clin Biochem, 47, pp.196~200 (2014)
- Filmus J, "Glypicans", Genome Biol, 9, pp.224~ (2008)
- Filmus J, "Glypican-3: a marker and a therapeutic target in hepatocellular carcinoma", FEBS J, 280, pp.2471~2476 (2013)
- Hippo Y, "Identification of soluble NH2-terminal fragment of glypican-3 as a serological marker for early-stage hepatocellular carcinoma", Cancer Res, 64, pp.2418~2423 (2004)
- Jia X, "Diagnosis accuracy of serum glypican-3 in patients with hepatocellular carcinoma: a systematic review with meta-analysis", Arch Med Res, 45, pp.580~588 (2014)
- Yasuda E, "Evaluation for clinical utility of GPC3, measured by a commercially available ELISA kit with Glypican-3 (GPC3) antibody, as a serological and histological marker for hepatocellular carcinoma", Hepatol Res, 40, pp.477~485 (2010)
- Ozkan H, "Diagnostic and prognostic role of serum glypican 3 in patients with hepatocellular carcinoma", J Clin Lab Anal, 25, pp.350~353 (2011)
- Beale G, "AFP, PIVKAII, GP3, SCCA-1 and follisatin as surveillance biomarkers for hepatocellular cancer in non-alcoholic and alcoholic fatty liver disease", BMC Cancer, 8, pp.200~ (2008)
- Wang Y, "Golgi protein 73, not Glypican-3, may be a tumor marker complementary to alpha-Fetoprotein for hepatocellular carcinoma diagnosis", J Gastroenterol Hepatol, 29, pp.597~602 (2014)
- 이현정, "Clinical Utility of Plasma Glypican-3 and Osteopontin as Biomarkers of Hepatocellular Carcinoma", Gut and Liver, 8(2), pp.177~185 (2014), 거트앤리버 발행위원회
- Badr EAE, "Role of serum glypican-3 in the diagnosis and differentiation of small hepatocellular carcinoma from hepatitis-C virus cirrhosis", Alexandria Med J, 50, pp.221~226 (2014)
- Abd El Gawad IA, "Comparing Prothrombin induced by vitamin K absence-II (PIVKA-II) with the oncofetal proteins Glypican-3, Alpha feto protein and Carcinoembryonic antigen in diagnosing hepatocellular carcinoma among Egyptian patients", J Egypt Natl Canc Inst, 26, pp.79~85 (2014)
- El-Shenawy S, "Abd El-Raof M, Allam M, Fath Allah S. Diagnostic role of serum Glypican-3 as a tumor marker for hepatocellular carcinoma", Nat Sci, 10, pp.32~38 (2012)
- Chen M, "Reevaluation of glypican- 3 as a serological marker for hepatocellular carcinoma", Clin Chim Acta, 423, pp.105~111 (2013)
- Tangkijvanich P, "Diagnostic role of serum glypican-3 in differentiating hepatocellular carcinoma from non-malignant chronic liver disease and other liver cancers", J Gastroenterol Hepatol, 25, pp.129~137 (2010)
- Traister A, "Mammalian Notum induces the release of glypicans and other GPI-anchored proteins from the cell surface", Biochem J, 410, pp.503~511 (2008)
- Capurro M, "Glypican-3 as a serum marker for hepatocellular carcinoma", Cancer Res, 65, pp.372~ (2005)
- Zittermann SI, "Soluble glypican 3 inhibits the growth of hepatocellular carcinoma in vitro and in vivo", Int J Cancer, 126, pp.1291~1301 (2010)
- Bedossa P, "Hepatocellular Carcinoma, Vol I", pp.489~501 (2011), Elsevier Inc